Seattle, WA, United States of America

Mirna Mujacic

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Mirna Mujacic: A Trailblazer in Genetic Engineering

Introduction

Mirna Mujacic, based in Seattle, Washington, is an innovative inventor recognized for her contributions to genetic engineering, particularly in the field of immunotherapy. With a remarkable portfolio that includes five patents, Mujacic is at the forefront of developing advanced techniques for producing genetically engineered cell compositions that hold the potential to revolutionize treatments for various diseases.

Latest Patents

Mujacic's latest patents focus on methods for producing genetically engineered cell compositions and related compositions. These methods involve generating engineered cells, which express recombinant receptors. Notably, her approach includes stimulating and engineering an input composition with a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. The processes she has developed enable the engineering of T cells with genetically engineered receptors, such as engineered T-cell receptors (TCRs) and chimeric antigen receptors (CARs), among other recombinant chimeric receptors. A significant aspect of her innovations is that they aim to produce T cell products that are more consistent, predictable, and exhibit lower toxicity compared to existing methods.

Career Highlights

Throughout her career, Mirna Mujacic has worked with renowned companies such as Amgen Inc. and Juno Therapeutics GmbH. Her experience in these leading organizations has allowed her to refine her skills and make substantial advancements in the field of genetic engineering. Mujacic's work continues to push the boundaries of what's possible in developing targeted cell therapies.

Collaborations

Mujacic has collaborated with notable individuals in her field, including Sandhya Pande and Ayu Rahardjo. These collaborations have provided opportunities for knowledge exchange and have played a crucial role in the successful development of her innovative methods and compositions.

Conclusion

In summary, Mirna Mujacic exemplifies the innovative spirit necessary in the realm of genetic engineering. Her patented methods for producing genetically engineered cell compositions are pioneering advancements that could significantly alter the landscape of therapeutic applications. With a strong background in reputable companies and valuable collaborations, Mujacic's contributions mark her as a leading figure in her field, paving the way for future breakthroughs in health and medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…